– Reuters
eFFECTOR Therapeutics Announces Topline Results Of Phase 2 KICKSTART Trial Of Tomivosertib Combined With Pembrolizumab In Non-Small Cell Lung Cancer
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the